Rare variants in the ATMgene and risk of breast cancer
Open Access
- 25 July 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in Breast Cancer Research
- Vol. 13 (4), R73
- https://doi.org/10.1186/bcr2919
Abstract
The ataxia-telangiectasia mutated (ATM) gene (MIM ID 208900) encodes a protein kinase that plays a significant role in the activation of cellular responses to DNA double-strand breaks through subsequent phosphorylation of central players in the DNA damage-response pathway. Recent studies have confirmed that some specific variants in the ATM gene are associated with increased breast cancer (BC) risk. However, the magnitude of risk and the subset of variants that are pathogenic for breast cancer remain unresolved. To investigate the role of ATM in BC susceptibility, we studied 76 rare sequence variants in the ATM gene in a case-control family study of 2,570 cases of breast cancer and 1,448 controls. The variants were grouped into three categories based on their likely pathogenicity, as determined by in silico analysis and analyzed by conditional logistic regression. Likely pathogenic sequence variants were genotyped in 129 family members of 27 carrier probands (15 of which carried c.7271T > G), and modified segregation analysis was used to estimate the BC penetrance associated with these rare ATM variants. In the case-control analysis, we observed an odds ratio of 2.55 and 95% confidence interval (CI, 0.54 to 12.0) for the most likely deleterious variants. In the family-based analyses, the maximum-likelihood estimate of the increased risk associated with these variants was hazard ratio (HR) = 6.88 (95% CI, 2.33 to 20.3; P = 0.00008), corresponding to a 60% cumulative risk of BC by age 80 years. Analysis of loss of heterozygosity (LOH) in 18 breast tumors from women carrying likely pathogenic rare sequence variants revealed no consistent pattern of loss of the ATM variant. The risk estimates from this study suggest that women carrying the pathogenic variant, ATM c.7271T > G, or truncating mutations demonstrate a significantly increased risk of breast cancer with a penetrance that appears similar to that conferred by germline mutations in BRCA2.This publication has 38 references indexed in Scilit:
- Progesterone receptor gene variants and risk of endometrial cancerCarcinogenesis: Integrative Cancer Research, 2010
- Missense Variants in ATM in 26,101 Breast Cancer Cases and 29,842 ControlsCancer Epidemiology, Biomarkers & Prevention, 2010
- Rare, Evolutionarily Unlikely Missense Substitutions in ATM Confer Increased Risk of Breast CancerAmerican Journal of Human Genetics, 2009
- ClassifyingMLH1andMSH2variants using bioinformatic prediction, splicing assays, segregation, and tumor characteristicsHuman Mutation, 2009
- In silico analysis of missense substitutions using sequence-alignment based methodsHuman Mutation, 2008
- Common Breast Cancer-Predisposition Alleles Are Associated with Breast Cancer Risk in BRCA1 and BRCA2 Mutation CarriersAmerican Journal of Human Genetics, 2008
- A common coding variant in CASP8 is associated with breast cancer riskNature Genetics, 2007
- Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 StudiesAmerican Journal of Human Genetics, 2003
- Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population‐based studyGenetic Epidemiology, 2001
- Breast and Other Cancers in Families with Ataxia-TelangiectasiaThe New England Journal of Medicine, 1987